Why is Kodiak Sciences stock surging today?

Kodiak Sciences stock experienced a substantial surge of 31.9% during pre-market trading following the release of topline results from its DAYBREAK pivotal Phase 3 study. This clinical evaluation focused on two investigational therapies, Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer), in patients with wet age-related macular degeneration.

Kodiak Sciences hosted a webcast at 8:30 AM Eastern Time to share the findings, indicating that the data likely met or surpassed the study's primary endpoint of non-inferiority in visual acuity gains compared to the active comparator aflibercept. The DAYBREAK study holds significant commercial importance as it simultaneously examines two distinct molecular agents within a single registrational trial, offering two potential commercial opportunities.

Zenkuda, currently possessing a BLA-ready profile in diabetic retinopathy and retinal vein occlusion due to prior Phase 3 successes, could benefit from a positive DAYBREAK result to complete its wet AMD regulatory package. Prior to the data release, UBS had reaffirmed a Buy rating with an $80 price target, anticipating non-inferiority for tarcocimab and dosing intervals of roughly three to three-and-a-half months.

Another analyst maintained a Buy rating with a $58 target as recently as mid-September. The broader market did not provide any additional support on this day, with the Nasdaq declining 1.0%, the S&P 500 falling 0.6%, and the Dow slipping 0.5%, indicating that Kodiak Sciences' movement was driven solely by company-specific news. The retinal disease sector is competitive, with Kodiak Sciences targeting the approximately $15 billion anti-VEGF segment of the retinal vascular disease market alongside established agents.

However, a successful Phase 3 readout would greatly alleviate risks associated with the company's path to commercialization. The combination of a binary clinical catalyst delivering positive results, a well-supported analyst bullish case, and a pipeline of upcoming data windows through mid-2027 contributed to today's outsized pre-market move, lifting the stock price toward its 52-week high of $47.84 from a 52-week low of $10.94.